Market Place
Sourcing Support
KSQ Therapeutics Doses 1st Patient in Ph 1/2 Study for KSQ-004EX
09 Apr 2025 //
GLOBENEWSWIRE
KSQ Therapeutics Appoints Kristen Hege, to its Board of Directors
05 Mar 2025 //
GLOBENEWSWIRE
KSQ Therapeutics Appoints John Lepore To Board
22 Oct 2024 //
GLOBENEWSWIRE
KSQ Therapeutics Appoints Anna Truppel-Hartmann As CMO
08 Oct 2024 //
GLOBENEWSWIRE
KSQ Therapeutics Gets FDA Clearance for KSQ-004EX IND Application
24 Sep 2024 //
GLOBENEWSWIRE
KSQ Therapeutics to Participate in Upcoming Investor Conferences
28 Aug 2024 //
GLOBENEWSWIRE
KSQ Doses First Patient With KSQ-001EX CRISPR-Engineered TILs
12 Jun 2024 //
GLOBENEWSWIRE
KSQ Therapeutics and CTMC Announce Strategic Collaboration
06 Sep 2023 //
BUSINESSWIRE
Roche inks KSQ deal to expand stable of synthetic lethal assets
13 Jul 2023 //
FIERCE BIOTECH
Takeda puts $510M on the line to expand KSQ cancer collaboration
18 May 2023 //
FIERCE BIOTECH
Japan`s Ono signs up for KSQ`s preclinical cancer programs
26 Jan 2023 //
BUSINESSWIRE
KSQ Appoints Mahesh Karande to its Board of Directors
08 Dec 2022 //
BUSINESSWIRE
KSQ Announces First Patient Dosed in Combination Portion of PI Study of KSQ-4279
07 Dec 2022 //
BUSINESSWIRE
KSQ Therapeutics Announces Leadership and Board Additions
23 Sep 2022 //
BUSINESSWIRE
KSQ Tx to Present Data at the AACR 2022 Annual Meeting
22 Mar 2022 //
BUSINESSWIRE
KSQ Therapeutics Doses First Patient in PI Study of KSQ-4279 in Solid Tumors
14 Sep 2021 //
BUSINESSWIRE
Takeda eyes pathway to natural killer therapies, teeing up $100M to partner KSQ
14 Jan 2021 //
ENDPTS
KSQ Therapeutics and Takeda Enter Broad Strategic Collaboration to Research
13 Jan 2021 //
BUSINESSWIRE
KSQ Therapeutics to Present New Data at EORTC-NCI-AACR Symposium
24 Sep 2020 //
BUSINESSWIRE
CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement
15 Oct 2019 //
BIOSPACE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.